Affiliation:
1. Pediatric Cancer Center Barcelona, 08950 Barcelona, Spain
2. Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Abstract
Monoclonal antibodies (mAbs), as the name implies, are clonal antibodies that bind to the same antigen. mAbs are broadly used as diagnostic or therapeutic tools for neoplasms, autoimmune diseases, allergic conditions, and infections. Although most mAbs are approved for treating adult cancers, few are applicable to childhood malignancies, limited mostly to hematological cancers. As for solid tumors, only anti-disialoganglioside (GD2) mAbs are approved specifically for neuroblastoma. Inequities of drug access have continued, affecting most therapeutic mAbs globally. To understand these challenges, a deeper dive into the complex transition from basic research to the clinic, or between marketing and regulatory agencies, is timely. This review focuses on current mAbs approved or under investigation in pediatric cancer, with special attention on solid tumors and anti-GD2 mAbs, and the hurdles that limit their broad global access. Beyond understanding the mechanisms of drug resistance, the continual discovery of next generation drugs safer for children and easier to administer, the discovery of predictive biomarkers to avoid futility should ease the acceptance by patient, health care professionals and regulatory agencies, in order to expand clinical utility. With a better integration into the multimodal treatment for each disease, protocols that align with the regional clinical practice should also improve acceptance and cost-effectiveness. Communication and collaboration between academic institutions, pharmaceutical companies, and regulatory agencies should help to ensure accessible, affordable, and sustainable health care for all.
Reference178 articles.
1. Aus Der Sitzung Der Medicinischen Section Vom 13 November 1867;Busch;Berl. Klin. Wochenschr.,1868
2. The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas;McCarthy;Iowa Orthop. J.,2006
3. Monoclonal Antibody Therapeutics: History and Future;Buss;Curr. Opin. Pharmacol.,2012
4. The History of Monoclonal Antibody Development—Progress, Remaining Challenges and Future Innovations;Liu;Ann. Med. Surg. (Lond.),2014
5. Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity;Milstein;Nature,1975
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献